335 related articles for article (PubMed ID: 30459761)
1. The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.
Pepys MB
Front Immunol; 2018; 9():2382. PubMed ID: 30459761
[TBL] [Abstract][Full Text] [Related]
2. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
Richards DB; Cookson LM; Barton SV; Liefaard L; Lane T; Hutt DF; Ritter JM; Fontana M; Moon JC; Gillmore JD; Wechalekar A; Hawkins PN; Pepys MB
Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298867
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component.
Mikolajek H; Kolstoe SE; Pye VE; Mangione P; Pepys MB; Wood SP
J Mol Recognit; 2011; 24(2):371-7. PubMed ID: 21360619
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro.
Ozawa D; Nomura R; Mangione PP; Hasegawa K; Okoshi T; Porcari R; Bellotti V; Naiki H
Sci Rep; 2016 Jul; 6():29077. PubMed ID: 27380955
[TBL] [Abstract][Full Text] [Related]
5. Binding of human serum amyloid P-component to phosphocholine.
Christner RB; Mortensen RF
Arch Biochem Biophys; 1994 Nov; 314(2):337-43. PubMed ID: 7979374
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.
Al-Shawi R; Tennent GA; Millar DJ; Richard-Londt A; Brandner S; Werring DJ; Simons JP; Pepys MB
Open Biol; 2016 Feb; 6(2):150202. PubMed ID: 26842068
[TBL] [Abstract][Full Text] [Related]
7. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
Richards D; Millns H; Cookson L; Lukas MA
Orphanet J Rare Dis; 2022 Jul; 17(1):259. PubMed ID: 35810311
[TBL] [Abstract][Full Text] [Related]
8. Pattern recognition by pentraxins.
Agrawal A; Singh PP; Bottazzi B; Garlanda C; Mantovani A
Adv Exp Med Biol; 2009; 653():98-116. PubMed ID: 19799114
[TBL] [Abstract][Full Text] [Related]
9. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component.
Bottazzi B; Vouret-Craviari V; Bastone A; De Gioia L; Matteucci C; Peri G; Spreafico F; Pausa M; D'Ettorre C; Gianazza E; Tagliabue A; Salmona M; Tedesco F; Introna M; Mantovani A
J Biol Chem; 1997 Dec; 272(52):32817-23. PubMed ID: 9407058
[TBL] [Abstract][Full Text] [Related]
10. Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP).
Swanson SJ; Christner RB; Mortensen RF
Biochim Biophys Acta; 1992 Dec; 1160(3):309-16. PubMed ID: 1477104
[TBL] [Abstract][Full Text] [Related]
11. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
[TBL] [Abstract][Full Text] [Related]
12. Serum amyloid P component binds to histones and activates the classical complement pathway.
Hicks PS; Saunero-Nava L; Du Clos TW; Mold C
J Immunol; 1992 Dec; 149(11):3689-94. PubMed ID: 1431140
[TBL] [Abstract][Full Text] [Related]
13. Investigating interactions of the pentraxins serum amyloid P component and C-reactive protein by mass spectrometry.
Aquilina JA; Robinson CV
Biochem J; 2003 Oct; 375(Pt 2):323-8. PubMed ID: 12892563
[TBL] [Abstract][Full Text] [Related]
14. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein.
Pepys MB; Baltz ML
Adv Immunol; 1983; 34():141-212. PubMed ID: 6356809
[TBL] [Abstract][Full Text] [Related]
15. Structural recognition and functional activation of FcgammaR by innate pentraxins.
Lu J; Marnell LL; Marjon KD; Mold C; Du Clos TW; Sun PD
Nature; 2008 Dec; 456(7224):989-92. PubMed ID: 19011614
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
Pepys MB
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
Bodin K; Ellmerich S; Kahan MC; Tennent GA; Loesch A; Gilbertson JA; Hutchinson WL; Mangione PP; Gallimore JR; Millar DJ; Minogue S; Dhillon AP; Taylor GW; Bradwell AR; Petrie A; Gillmore JD; Bellotti V; Botto M; Hawkins PN; Pepys MB
Nature; 2010 Nov; 468(7320):93-7. PubMed ID: 20962779
[TBL] [Abstract][Full Text] [Related]
19. Serum amyloid P component promotes formation of distinct aggregated lysozyme morphologies and reduces toxicity in Drosophila flies expressing F57I lysozyme.
Bergkvist L; Richards DR; Bernardo-Gancedo A; Kumita JR; Nilsson PR; Brorsson AC
PLoS One; 2020; 15(1):e0227227. PubMed ID: 31978114
[TBL] [Abstract][Full Text] [Related]
20. Science and serendipity.
Pepys MB
Clin Med (Lond); 2007 Dec; 7(6):562-78. PubMed ID: 18193704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
